RxDoctor Payments DataLook up a doctor →

Stacy Moran, PA

Physician Assistant · Indiana, PANPI 1295849859

Payments from drug & device makers

$27,691in general payments, 2019–2025

Across 626 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$808
  • Otsuka America Pharmaceutical, Inc.$719
  • Lundbeck LLC$481
  • Vanda Pharmaceuticals Inc.$429
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$17,60064%
  • Travel & lodging$480%
  • Food & beverage$9,52434%
  • Education$5192%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,691 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,404
Medicare patients
27
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine32$297,859
IngrezzaValbenazine Tosylate29$230,480
VraylarCariprazine Hcl117$180,803
Abilify MaintenaAripiprazole28$78,454
Fluphenazine Hcl25$11,762
TrintellixVortioxetine Hydrobromide23$10,749
Aripiprazole294$10,118
Lurasidone Hcl25$8,945
LamictalLamotrigine12$6,912
Trazodone Hcl537$5,197
Perphenazine69$4,217
Bupropion XlBupropion Hcl244$4,038
Sertraline Hcl321$3,792
Lamotrigine375$3,775
Quetiapine Fumarate190$3,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$2,459$297,85932 claims
Neurocrine Biosciences, Inc.Ingrezza$808$230,48029 claims
AbbVieVraylar$19,302$180,803117 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$719$78,45428 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$23$10,74923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →